Document is current
Any future updates will be listed below
-
Authors
Späth, Martin R.
Arjune, Sita
Bohl, Katrin
Rinschen, Markus M.
Falk, Christine S.
Antczak, Philipp
Grundmann, Franziska
Kubacki, Torsten
Hoyer-Allo, K. Johanna R.
Ignarski, Michael
Koehler, Felix C.
Kaufmann, Kathrin
Bartram, Malte P.
Wagner, Tristan
Thomas, Michael
Lackmann, Jan Wilm
Wahida, Adam
Schmaderer, Christoph
Kemmner, Stephan
Kurschat, Christine E.
Benzing, Thomas
Stippel, Dirk
Burst, Volker
Müller, Roman-Ulrich
-
Funding
Funding for this research was provided by:
Cologne Clinician Scientist Program (CCSP), Faculty of Medicine, University of Cologne (DFG, FI 773/15-1)
Dr. Werner Jackstädt-Stiftung
Koeln Fortune Program, Faculty of Medicine, University of Cologne
DGfN/DGEM-Stipendium 2016
Köln Fortune Programm
CECAD-Rotationsprogramm
KFH-Stiftung
Köln Fortune Program / Faculty of Medicine, University of Cologne
Deutsche Forschungsgemeinschaft, Germany (GR 3932/2-2)
Deutsche Forschungsgemeinschaft, Germany (Germany's Excellence Strategy - EXC 2030 - 390661388)
“Gusyk”-Familienförderstellen, Faculty of Medicine, University of Cologne
Cologne Clinician Scientist Program (CCSP) / Faculty of Medicine / University of Cologne, funded by the Deutsche Forschungsgemeinschaft (Project No. 413543196)
Else Kröner-Fresenius-Stiftung
Deutsche Forschungsgemeinschaft (EXC 2030: CECAD – Excellent in Aging Research - Project number 390661388)
Koeln Fortune program / Faculty of Medicine, University of Cologne
Ministry of Science North Rhine-Westphalia (Nachwuchsgruppen.NRW 2015-2021)
the German Federal Ministry of Education and Research
Marga and Walter Boll Foundation
PKD Foundation
- License Information
-
More Information
Article History
Received: 2 November 2025
Accepted: 29 April 2026
First Online: 28 May 2026
Competing interests
: The Dept. II of Internal Medicine received research funding from Otsuka Pharmaceuticals, Fresenius Kabi and Thermo Fisher Scientific. RUM served as an advisor to pharmaceutical industry in projects not directly related to the manuscript at-hand (Alnylam, AICURIS, GSK, Novartis, Vertex).
